Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jasper Therapeutics, Inc.JSPR · Entity 7588 | Director | October 13, 2023 | October 13, 2023 |
| PORTOLA PHARMACEUTICALS INCPTLA · Entity 147987 | Director · Chief Executive Officer | July 28, 2018 | August 28, 2018 |
| Zai Lab LtdZLAB · Entity 4271 | Director | August 12, 2026 | August 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jasper Therapeutics, Inc.
Report date October 13, 2023 · Filed October 13, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Voting Common StockSEC Table I · non-derivative | Direct | 53,521 |
Reported balance
After 2023-10-13 transaction · row 1
1 source rowRow 1 · 2023-10-13 · Sale · Disposed 7,965 · Balance 53,521 F1: The transaction reported in this Form 4 was effected pursuant to a trading plan intended to comply with Rule 10b5-1(c) and adopted by the Reporting Person on June 15, 2023. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.84 to $0.8717, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 was effected pursuant to a trading plan intended to comply with Rule 10b5-1(c) and adopted by the Reporting Person on June 15, 2023.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.84 to $0.8717, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.
PORTOLA PHARMACEUTICALS INC
Report date July 28, 2018 · Filed August 28, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 204,448 |
Ending reported balance
After 2018-08-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-07-28 · Exercise / conversion · Acquired 35,000 · Balance 222,035 F1: Each Performance Stock Unit ("PSU") granted on January 27, 2015 pursuant to the Issuer's 2013 Equity Incentive Plan represented a contingent right to receive one share of Issuer's Common Stock. These PSUs were earned based on achievement of the market performance conditions and were subject to an additional one year period of service. 50% of the PSUs vested on July 28, 2018 and 50% will vest on August 31, 2018. Row 2 · 2018-08-23 · Tax withholding · Disposed 17,587 · Balance 204,448 F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). |
Filing footnotes · ownership attribution and instrument terms
F1: Each Performance Stock Unit ("PSU") granted on January 27, 2015 pursuant to the Issuer's 2013 Equity Incentive Plan represented a contingent right to receive one share of Issuer's Common Stock. These PSUs were earned based on achievement of the market performance conditions and were subject to an additional one year period of service. 50% of the PSUs vested on July 28, 2018 and 50% will vest on August 31, 2018.
F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
Zai Lab Ltd
Report date August 12, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 41,931 |
Reported balance
After 2026-08-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-12 · Sale · Disposed 8,506 · Balance 41,931 F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Eidos Therapeutics, Inc.
Report date January 26, 2021 · Filed January 28, 2021
Section 16 reporting ended · disclosed 2021-01-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.51 · Expires 2030-05-27 | Direct | 0 |
Reported balance
After 2021-01-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-26 · Disposition to issuer · Disposed 21,528 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). F2: (Continued from footnote 1) The option vests in a single installment on May 27, 2021. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.87 · Expires 2029-06-11 | Direct | 0 |
Reported balance
After 2021-01-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-26 · Disposition to issuer · Disposed 21,528 · Balance 0 F3: The option vests in a single installment on May 27, 2021. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.67 · Expires 2028-12-04 | Direct | 0 |
Reported balance
After 2021-01-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-01-26 · Disposition to issuer · Disposed 43,056 · Balance 0 F4: The option vests in three annual installments after December 4, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time").
F2: (Continued from footnote 1) The option vests in a single installment on May 27, 2021. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time.
F3: The option vests in a single installment on May 27, 2021. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time.
F4: The option vests in three annual installments after December 4, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2026 Filed Aug 13, 2026 20:15 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleAmerican Depositary Shares | 8,506 | $25.00 | $212,650.00 |
DisclosureSEC source: 0000905148-26-003620 · form4.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,931 F1 · security: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:05 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleAmerican Depositary Shares | 7,040 | $18.09 | $127,353.60 |
DisclosureSEC source: 0000905148-26-003077 · form4.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,437 F1 · security: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:08 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantAmerican Depositary Shares | 22,371 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-003031 · form4.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,477 F1 · security: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · shares: Represents restricted shares that vest in full on June 17, 2027, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date. Read SEC document |
| June 20, 2025 Filed Jun 23, 2025 20:10 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleAmerican Depositary Shares | 13,814 | $35.67 | $492,745.38 |
DisclosureSEC source: 0000905148-25-002215 · form4.xml · nonDerivative · entry 2 Lis William · CIK 0001574558 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,106 F1 · security: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F3 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2025. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:10 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantAmerican Depositary Shares | 10,831 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-002215 · form4.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,920 F1 · security: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · shares: Represents restricted shares that vest in full on June 18, 2026, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 22:11 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleAmerican Depositary Shares | 15,000 | $32.98 | $494,700.00 |
DisclosureSEC source: 0000905148-25-000827 · form4.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,089 F1 · security: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2024. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 18:04 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleAmerican Depositary Shares | 100 | $18.04 | $1,804.00 |
DisclosureSEC source: 0000905148-24-001839 · form4.xml · nonDerivative · entry 2 Lis William · CIK 0001574558 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,089 F1 · security: Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 1, 2024. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 18:04 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleAmerican Depositary Shares | 10,297 | $17.31 | $178,281.23 |
DisclosureSEC source: 0000905148-24-001839 · form4.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,189 F1 · security: Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 1, 2024. F3 · price: Reflects a weighted average sale price of $17.3139 per share, at prices ranging from $17.02 to $17.96 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 21:00 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantAmerican Depositary Shares | 21,253 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001748 · form4.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,486 F1 · security: Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · shares: Represents restricted shares that vest in full on June 18, 2025, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date. Read SEC document |
| October 13, 2023 Filed Oct 13, 2023 22:56 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | SaleVoting Common Stock | 7,965 | $0.85 | $6,776.62 |
DisclosureSEC source: 0001013762-23-003901 · ownership.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,521 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a trading plan intended to comply with Rule 10b5-1(c) and adopted by the Reporting Person on June 15, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.84 to $0.8717, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 20:05 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantAmerican Depositary Shares | 18,903 | $26.45 | $499,984.35 |
DisclosureSEC source: 0000950170-23-031097 · ownership.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,233 F1 · security: Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 22:42 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 47,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001213900-23-047568 · ownership.xml · derivative · entry 1 Lis William · CIK 0001574558 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 Underlying: Voting Common Stock · 47,000 shares Expires 2033-06-07 Read SEC document |
| April 13, 2023 Filed Apr 14, 2023 20:14 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | SaleVoting Common Stock | 8,500 | $1.44 | $12,240.00 |
DisclosureSEC source: 0001213900-23-029888 · ownership.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,486 F1 · shares: These shares were sold by the Reporting Person solely in order to satisfy certain tax obligations in connection with the issuance of shares of the Issuer's common stock upon the vesting of restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:05 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleAmerican Depositary Shares | 5,434 | $38.31 | $208,176.54 |
DisclosureSEC source: 0000899243-23-007333 · doc4.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,330 F1 · security: Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · kind: The reported transaction was effected pursuant to a sale plan adopted by the Reporting Person, dated 12/30/2022, that expires on 05/31/2023 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| October 12, 2022 Filed Oct 13, 2022 23:58 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantVoting Common Stock | 29,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-063936 · ownership.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,986 F1 · shares: The reported securities are represented by restricted stock units, 1/2 of which shall vest on each of April 12, 2023 and October 12, 2023, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 20:01 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | SaleVoting Common Stock | 24,743 | $2.08 | $51,403.58 |
DisclosureSEC source: 0001213900-22-035570 · ownership.xml · nonDerivative · entry 2 Lis William · CIK 0001574558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,486 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.86 to $2.30, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 20:01 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | SaleVoting Common Stock | 24,743 | $2.02 | $50,030.35 |
DisclosureSEC source: 0001213900-22-035570 · ownership.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,229 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.88 to $2.24, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 22:01 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001213900-22-014562 · ownership.xml · derivative · entry 4 Lis William · CIK 0001574558 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Voting Common Stock · 100,000 shares Expires 2032-03-21 F4 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on April 15, 2022, and 1/12th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 22:01 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 89,972 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001213900-22-014562 · ownership.xml · derivative · entry 3 Lis William · CIK 0001574558 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,972 Underlying: Voting Common Stock · 89,972 shares Expires 2032-03-21 F3 · derivative.exercise_date: 1/4th of the shares subject to the option vested on March 21, 2022, and 1/4th of the shares subject to the option shall vest on each of March 24, 2022, September 24, 2022 and March 24, 2023, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 22:01 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001213900-22-014562 · ownership.xml · derivative · entry 2 Lis William · CIK 0001574558 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Voting Common Stock · 7,500 shares Expires 2032-03-21 F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on December 7, 2022, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 22:01 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantVoting Common Stock | 89,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-014562 · ownership.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,972 F1 · shares: The reported securities are represented by restricted stock units, 1/2 of which shall vest on each of June 24, 2022 and June 27, 2022, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| January 20, 2022 Filed Jan 21, 2022 22:10 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 1,926 | $53.40 | $102,848.40 |
DisclosureSEC source: 0001567619-22-001445 · doc1.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,114 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated September 1, 2021, expires January 28, 2022 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:12 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantOrdinary Shares | 7,763 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000397 · doc1.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,040 Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 19:06 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Disposition to issuerStock Option (Right to Buy) · Derivative | 43,056 | Not disclosed Strike: $13.67 | Not disclosed |
DisclosureSEC source: 0000899243-21-003644 · doc4.xml · derivative · entry 3 Lis William · CIK 0001574558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,056 shares Expires 2028-12-04 F4 · price: The option vests in three annual installments after December 4, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. F4 · derivative.exercise_date: The option vests in three annual installments after December 4, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 19:06 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Disposition to issuerStock Option (Right to Buy) · Derivative | 21,528 | Not disclosed Strike: $30.87 | Not disclosed |
DisclosureSEC source: 0000899243-21-003644 · doc4.xml · derivative · entry 2 Lis William · CIK 0001574558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,528 shares Expires 2029-06-11 F3 · price: The option vests in a single installment on May 27, 2021. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. F3 · derivative.exercise_date: The option vests in a single installment on May 27, 2021. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 19:06 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Disposition to issuerStock Option (Right to Buy) · Derivative | 21,528 | Not disclosed Strike: $48.51 | Not disclosed |
DisclosureSEC source: 0000899243-21-003644 · doc4.xml · derivative · entry 1 Lis William · CIK 0001574558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,528 shares Expires 2030-05-27 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). F2 · price: (Continued from footnote 1) The option vests in a single installment on May 27, 2021. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). F2 · derivative.exercise_date: (Continued from footnote 1) The option vests in a single installment on May 27, 2021. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:36 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantOrdinary Shares | 3,852 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002543 · doc4.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,277 Read SEC document |
| January 05, 2021 Filed Feb 14, 2022 21:05 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Tax withholdingOrdinary Shares | 5,350 | $129.14 | $690,899.00 |
DisclosureSEC source: 0000899243-22-006141 · doc5.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,927 F1 · kind: Disposition of shares to cover taxes. The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated December 4, 2020 and which expired January 5, 2021, and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| May 27, 2020 Filed May 29, 2020 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GrantStock Option (right to buy) · Derivative | 21,528 | $0.00 Strike: $48.51 | $0.00 |
DisclosureSEC source: 0000899243-20-014538 · doc4.xml · derivative · entry 1 Lis William · CIK 0001574558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,528 Underlying: Common Stock · 21,528 shares Expires 2030-05-27 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in a single installment on the earlier of (i) the first anniversary of the grant date, so that all of the underlying shares shall be vested on May 26, 2021, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service with the Issuer through the vesting date. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2018 Stock Option and Incentive Plan, as amended). Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 21:23 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GrantStock Option (right to buy) · Derivative | 21,528 | $0.00 Strike: $30.87 | $0.00 |
DisclosureSEC source: 0000899243-19-016951 · doc4.xml · derivative · entry 1 Lis William · CIK 0001574558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,528 Underlying: Common Stock · 21,528 shares Expires 2029-06-11 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in a single installment on the earlier of (i) the first anniversary of the grant date, so that all of the underlying shares shall be vested on June 12, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service with the Issuer through the vesting date. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2018 Stock Option and Incentive Plan, as amended). Read SEC document |
| December 04, 2018 Filed Dec 7, 2018 20:42 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GrantStock Option (right to buy) · Derivative | 43,056 | $0.00 Strike: $13.67 | $0.00 |
DisclosureSEC source: 0000899243-18-030438 · doc4.xml · derivative · entry 1 Lis William · CIK 0001574558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,056 Underlying: Common Stock · 43,056 shares Expires 2028-12-04 F1 · date: The option grant was approved by the Issuer's board of directors on December 4, 2018, and is subject to cancellation if the Issuer's shareholders do not approve an increase to the share reserve of the stock option plan under which the option was granted by December 4, 2019. F2 · derivative.exercise_date: The Reporting Person is a participant in the Issuer's 2018 Stock Option and Incentive Plan and received 43,056 stock options (the "Grant") on December 4, 2018. The Grant shall vest as follows: one-third of the stock options shall vest annually over a period of three (3) years following December 4, 2018 subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| August 23, 2018 Filed Aug 28, 2018 18:13 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Tax withholdingCommon Stock | 17,587 | $26.05 | $458,141.35 |
DisclosureSEC source: 0001209191-18-048736 · doc4.xml · nonDerivative · entry 2 Lis William · CIK 0001574558 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,448 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| July 28, 2018 Filed Aug 28, 2018 18:13 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-048736 · doc4.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each Performance Stock Unit ("PSU") granted on January 27, 2015 pursuant to the Issuer's 2013 Equity Incentive Plan represented a contingent right to receive one share of Issuer's Common Stock. These PSUs were earned based on achievement of the market performance conditions and were subject to an additional one year period of service. 50% of the PSUs vested on July 28, 2018 and 50% will vest on August 31, 2018. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 18:18 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | SaleCommon Stock | 5,113 | $45.21 | $231,158.73 |
DisclosureSEC source: 0001209191-18-036768 · doc4.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,035 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 13, 2017, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.54, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote to this Form 4. Read SEC document |
| May 22, 2018 Filed May 24, 2018 20:22 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Tax withholdingCommon Stock | 6,491 | $40.82 | $264,962.62 |
DisclosureSEC source: 0001209191-18-033237 · doc4.xml · nonDerivative · entry 2 Lis William · CIK 0001574558 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,148 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| May 22, 2018 Filed May 24, 2018 20:22 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 12,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033237 · doc4.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,639 F1 · shares: Each Performance Stock Unit ("PSU") granted January 30, 2017 represented a contingent right to receive one share of Issuer's Common Stock. 12,890 PSUs became vested upon the date of the Compensation Committee's certification of regulatory approval of Andexanet alfa in the United States in 2018. 12,891 PSUs will vest on the first anniversary of the Certification Date. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 17:55 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Tax withholdingCommon Stock | 19,184 | $32.53 | $624,055.52 |
DisclosureSEC source: 0001209191-18-017424 · doc4.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,624 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 20:15 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $51.31 | $0.00 |
DisclosureSEC source: 0001209191-18-007265 · doc4.xml · derivative · entry 2 Lis William · CIK 0001574558 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-01-30 F2 · derivative.exercise_date: The option shall vest as follows: 1/48th of the shares subject to the option shall vest each month after January 1, 2018, subject to the Reporting Person's Continuous Service as of each such date. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 20:15 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-007265 · doc4.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · shares: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSU vests annually over three years commencing on March 1, 2018, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 16:44 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Tax withholdingCommon Stock | 7,435 | $54.86 | $407,884.10 |
DisclosureSEC source: 0001209191-17-049634 · doc4.xml · nonDerivative · entry 1 Lis William · CIK 0001574558 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| June 28, 2017 Filed Jun 29, 2017 20:15 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,150 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001209191-17-042399 · doc4.xml · derivative · entry 16 Lis William · CIK 0001574558 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,820 Underlying: Common Stock · 14,150 shares Expires 2020-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017. Read SEC document |
| June 28, 2017 Filed Jun 29, 2017 20:15 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | SaleCommon | 14,150 | $55.35 | $783,202.50 |
DisclosureSEC source: 0001209191-17-042399 · doc4.xml · nonDerivative · entry 10 Lis William · CIK 0001574558 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.00 to $55.68, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4. F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017. Read SEC document |
| June 28, 2017 Filed Jun 29, 2017 20:15 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionCommon Stock | 14,150 | $9.00 | $127,350.00 |
DisclosureSEC source: 0001209191-17-042399 · doc4.xml · nonDerivative · entry 9 Lis William · CIK 0001574558 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 20:15 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $9.80 | $0.00 |
DisclosureSEC source: 0001209191-17-042399 · doc4.xml · derivative · entry 15 Lis William · CIK 0001574558 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,796 Underlying: Common Stock · 20,000 shares Expires 2023-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 20:15 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionStock Option (Right to Buy) · Derivative | 70,014 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001209191-17-042399 · doc4.xml · derivative · entry 14 Lis William · CIK 0001574558 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,014 shares Expires 2022-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 20:15 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,285 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001209191-17-042399 · doc4.xml · derivative · entry 13 Lis William · CIK 0001574558 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,285 shares Expires 2022-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 20:15 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $8.50 | $0.00 |
DisclosureSEC source: 0001209191-17-042399 · doc4.xml · derivative · entry 12 Lis William · CIK 0001574558 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,070 Underlying: Common Stock · 55,000 shares Expires 2021-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 20:15 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionStock Option (Right to Buy) · Derivative | 95,850 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001209191-17-042399 · doc4.xml · derivative · entry 11 Lis William · CIK 0001574558 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,970 Underlying: Common Stock · 95,850 shares Expires 2020-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 20:15 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | SaleCommon Stock | 13,100 | $56.57 | $741,067.00 |
DisclosureSEC source: 0001209191-17-042399 · doc4.xml · nonDerivative · entry 8 Lis William · CIK 0001574558 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.42 to $56.77, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4. F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 20:15 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | SaleCommon Stock | 112,778 | $55.90 | $6,304,290.20 |
DisclosureSEC source: 0001209191-17-042399 · doc4.xml · nonDerivative · entry 7 Lis William · CIK 0001574558 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,100 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.42 to $56.41, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4. F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16,2017 and amended on March 21, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.